Published in Trends Cell Biol on December 22, 2014
Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell (2017) 1.44
Immunotherapy and tumor microenvironment. Cancer Lett (2015) 0.88
Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer. Onco Targets Ther (2016) 0.86
Direct Interaction between Carcinoma Cells and Cancer Associated Fibroblasts for the Regulation of Cancer Invasion. Cancers (Basel) (2015) 0.85
A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses. Genes Dev (2016) 0.85
Cancer-Associated Myeloid Regulatory Cells. Front Immunol (2016) 0.85
Tolerance and immune suppression in the tumor microenvironment. Cell Immunol (2015) 0.84
Interferons and the Immunogenic Effects of Cancer Therapy. Trends Immunol (2015) 0.84
Emerging Techniques in Brain Tumor Imaging: What Radiologists Need to Know. Korean J Radiol (2016) 0.83
SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment. Oncogene (2016) 0.83
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. Cancer Res (2016) 0.83
Stromal Fibroblast in Age-Related Cancer: Role in Tumorigenesis and Potential as Novel Therapeutic Target. Front Oncol (2015) 0.82
Neural Regulation of Pancreatic Cancer: A Novel Target for Intervention. Cancers (Basel) (2015) 0.80
Tumor Interstitial Fluid Formation, Characterization, and Clinical Implications. Front Oncol (2015) 0.79
Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends Cancer (2015) 0.79
EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. Oncotarget (2016) 0.79
Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment. Oncotarget (2016) 0.78
Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer. Biomed Res Int (2015) 0.78
Therapeutic potential of chemokine signal inhibition for metastatic breast cancer. Pharmacol Res (2015) 0.78
Impacts of Ionizing Radiation on the Different Compartments of the Tumor Microenvironment. Front Pharmacol (2016) 0.78
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat Commun (2016) 0.78
A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma. Nucleic Acid Ther (2016) 0.78
Stem Cell Factor-Based Identification and Functional Properties of In Vitro-Selected Subpopulations of Malignant Mesothelioma Cells. Stem Cell Reports (2017) 0.78
Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget (2016) 0.77
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov (2016) 0.77
Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review. Oncotarget (2016) 0.77
Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Haematologica (2015) 0.77
β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases. Clin Exp Metastasis (2016) 0.77
Polarization of macrophages in the tumor microenvironment is influenced by EGFR signaling within colon cancer cells. Oncotarget (2016) 0.77
Ontogeny of Tumor-associated Macrophages and Its Implication in Cancer Regulation. Trends Cancer (2016) 0.77
Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma. Oncotarget (2016) 0.77
Targeting tumor metastases: Drug delivery mechanisms and technologies. J Control Release (2015) 0.76
Hormones and immunity in cancer: are thyroid hormones endocrine players in the microglia/glioma cross-talk? Front Cell Neurosci (2015) 0.76
Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries. Curr Opin Immunol (2017) 0.76
Targeting of crosstalk between tumor and tumor microenvironment by β-D mannuronic acid (M2000) in murine breast cancer model. Cancer Med (2017) 0.75
An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. Sci Rep (2017) 0.75
Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin. Oncotarget (2015) 0.75
Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. J Gastrointest Oncol (2016) 0.75
Targeting tumor-associated macrophages to combat pancreatic cancer. Oncotarget (2016) 0.75
Looking beyond the cancer cell for effective drug combinations. Genome Med (2016) 0.75
Immune Regulation of the Metastatic Process: Implications for Therapy. Adv Cancer Res (2016) 0.75
Intracranial Tumor Cell Migration and the Development of Multiple Brain Metastases in Malignant Melanoma. Transl Oncol (2016) 0.75
Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence. Elife (2017) 0.75
Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. Nat Commun (2016) 0.75
Effects of CIK on hypoxia inducible factor-1α and T-cell subsets on colon 26 cancer xenograft mice. Oncol Lett (2016) 0.75
Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res (2017) 0.75
Optical Windows for Imaging the Metastatic Tumour Microenvironment in vivo. Trends Biotechnol (2016) 0.75
Microenvironmental InterFereNce of metabolism regulates chemosensitivity. Cell Res (2016) 0.75
CXCL9: evidence and contradictions for its role in tumor progression. Cancer Med (2016) 0.75
Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy. EMBO Mol Med (2016) 0.75
Hypoxia-Related Marker GLUT-1, CAIX, Proliferative Index and Microvessel Density in Canine Oral Malignant Neoplasia. PLoS One (2016) 0.75
Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients. Oncotarget (2015) 0.75
Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cells. Oncol Lett (2017) 0.75
Profiling networks of distinct immune-cells in tumors. BMC Bioinformatics (2016) 0.75
Inhibition of Lysyl Oxidases Impairs Migration and Angiogenic Properties of Tumor-Associated Pericytes. Stem Cells Int (2017) 0.75
Quantitative investigation of MDA-MB-231 breast cancer cell motility: dependence on epidermal growth factor concentration and its gradient. Mol Biosyst (2017) 0.75
The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells. Oncotarget (2017) 0.75
Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy. Cell Mol Immunol (2017) 0.75
Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents. Cell Rep (2017) 0.75
Suppression of Akt1- β-catenin pathway in advanced prostate cancer promotes TGFβ1-mediated epithelial to mesenchymal transition and metastasis. Cancer Lett (2017) 0.75
Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. Oncotarget (2017) 0.75
Oligo-Fucoidan prevents IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression. Sci Rep (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Tensional homeostasis and the malignant phenotype. Cancer Cell (2005) 19.30
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell (2009) 14.40
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55
Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 11.16
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med (2014) 9.09
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res (1999) 8.63
The extracellular matrix: not just pretty fibrils. Science (2009) 8.52
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol (2009) 7.74
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57
A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res (2004) 7.56
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell (2004) 6.99
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Cancer invasion and the microenvironment: plasticity and reciprocity. Cell (2011) 6.36
The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol (2012) 6.07
High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer (2004) 5.99
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell (2014) 5.87
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res (2004) 5.65
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell (2002) 5.56
Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell (2014) 5.38
Tumor induction of VEGF promoter activity in stromal cells. Cell (1998) 5.20
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 5.16
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer (2005) 5.07
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell (2009) 4.47
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol (2005) 4.45
"Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med (2008) 4.38
Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer (2005) 4.16
Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol (2008) 4.05
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 4.02
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
Tumors as organs: complex tissues that interface with the entire organism. Dev Cell (2010) 3.98
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med (2009) 3.86
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature (2012) 3.83
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest (2010) 3.74
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell (2009) 3.71
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood (2008) 3.67
Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res (2008) 3.59
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev (2010) 3.56
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 3.53
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev (2008) 3.50
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res (2008) 3.50
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 3.50
Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer (2009) 3.49
The perivascular niche regulates breast tumour dormancy. Nat Cell Biol (2013) 3.36
Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest (2003) 3.31
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med (2012) 3.21
The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res (2006) 3.07
Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell (2014) 3.04
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev (2011) 3.04
Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol (2008) 3.02
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med (2013) 3.00
A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol (2013) 2.98
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell (2013) 2.98
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
DNA damage-mediated induction of a chemoresistant niche. Cell (2010) 2.94
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89